Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib adjuvant therapy in MRD-positive EGFR-mutant stage IA2-IB NSCLC
ChiCTR2300070717Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 3-year disease-free survival rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300070717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070717.